GBMs prioritize the assessment and inclusion of MGMT promoter methylation as an essential component of molecular diagnostics and treatment for all high-grade gliomas (grades 3 and 4) where studies have reported that up to 60% of GBMs cases exhibit MGMT promoter methylation [4,9,11,12,13]. Here, MGMT is linked to central nervous system cancer.